Skip to main content
BIOTRON LIMITED logo

BIOTRON LIMITED — Investor Relations & Filings

Ticker · BIT ISIN · AU000000BIT4 ASX Professional, scientific and technical activities
Open in API
Filings indexed 766 across all filing types
Latest filing 2011-03-01 Share Issue/Capital Cha…
Country AU Australia
Listing ASX BIT

About BIOTRON LIMITED

https://www.biotron.com.au

Biotron Limited is a clinical-stage company focused on the development of novel small molecule antiviral therapeutics. The company utilizes its proprietary ViroPore technology platform to design and develop drugs that target viroporins—a class of proteins found in a wide range of viruses that play critical roles in viral replication and the evasion of host immune responses. Biotron's primary clinical program centers on BIT225, a first-in-class inhibitor targeting the HIV-1 Vpu protein and the Hepatitis C virus p7 protein. The company aims to address unmet medical needs by developing treatments that can potentially eradicate viral reservoirs and improve patient outcomes. In addition to HIV and HCV, Biotron is exploring the application of its antiviral platform against other significant viral pathogens, including SARS-CoV-2, leveraging its expertise in ion channel-targeting chemistry to disrupt the viral life cycle.

Recent filings

Filing Released Lang Actions
Appendix 3B 8 pages 76.5KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 3B form, which is a New Issue Announcement and Application for Quotation of Additional Securities submitted to the ASX (Australian Securities Exchange). It details the issuance of 5,000 fully paid ordinary shares upon exercise of options, including terms, issue price, and quotation details. The document is a regulatory announcement about a capital change (new shares issued and application for quotation) rather than a full financial report or earnings release. It does not contain financial statements or management discussion but focuses on the issuance and quotation of securities. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length is over 10,000 characters and contains detailed information about the share issue, confirming it is not a brief announcement or a report publication notice.
2011-03-01 English
Half Yearly Report and Accounts 19 pages 190.4KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM FINANCIAL REPORT FOR THE HALF YEAR ENDED 31 DECEMBER 2010' and includes detailed financial statements such as the Directors' Report, Condensed Interim Statement of Comprehensive Income, Statement of Financial Position, Cash Flows, and Notes to the Financial Report. It also contains an Independent Auditor’s Review Report. The document references compliance with Listing Rule 4.2A and is clearly a comprehensive financial report for a half-year period, not just an announcement or summary. The length is substantial (15,000 characters), indicating it is the full report, not a brief notice or publication announcement. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2011
2011-02-27 English
Biotron Share Purchase Plan 7 pages 109.8KB
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement and offer regarding a Share Purchase Plan (SPP) by Biotron Limited. It discusses the terms of the SPP, the issue price, the purpose of the capital raising, eligibility, and instructions for participation. The content focuses on raising capital through issuing new shares to existing shareholders at a discount. There is no financial statement, earnings data, or management discussion of financial results. The document is not a report but an announcement and offer related to capital raising activities. Therefore, it fits the category of Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2011-02-23 English
Response to ASX Query re Appendix 4C 4 pages 47.3KB
Regulatory Filings Classification · 95% confidence The document is a letter from Biotron Limited responding to ASX Compliance Pty Ltd regarding the company's cash expenditure, clinical trial progress, and compliance with ASX Listing Rules. It references the company's Quarterly Report in the form of an Appendix 4C for the period ended 31 December 2010, which is a quarterly cash flow report. The content focuses on operational cash flow, funding, and compliance with listing rules rather than presenting actual financial statements or detailed financial analysis. The document is a regulatory response letter to ASX queries about the quarterly report and company status, not the quarterly report itself. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2011-02-06 English
Appendix 4C - quarterly 5 pages 52.5KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and contains detailed financial data including consolidated statement of cash flows, cash flow related to operating, investing, and financing activities, reconciliation of cash, and compliance statements. The document covers a quarterly period ending 31 December 2010 and includes substantive financial data and analysis. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year and contains actual financial statements. The document is not a brief announcement or a certification, but a full quarterly financial report. Therefore, the correct classification is IR with high confidence. H1 2011
2011-01-26 English
US BIOTECH SHOWCASE PRESENTATION 18 pages 1.9MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation by Biotron Limited's Managing Director at the Biotech Showcase 2011, including extensive information about the company's drug development pipeline, clinical trials, financial highlights, and strategic positioning. It contains forward-looking statements, clinical trial data, market analysis, and company background. The document is not a formal regulatory filing like an annual or interim report, nor is it an announcement of voting results, legal proceedings, or capital changes. It is a comprehensive presentation aimed at investors and stakeholders to update them on the company's activities and prospects. Therefore, it fits the definition of an Investor Presentation (IP). The document length (over 13,000 characters) and content confirm it is the presentation itself, not just an announcement or summary.
2011-01-11 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.